Yong Bao1, Fang Peng2, Qi-Chao Zhou3, Zhong-Hua Yu4, Jian-Cheng Li5, Zhi-Bin Cheng6, Long Chen7, Xiao Hu3, Yuan-Yuan Chen8, Jin Wang8, Yan Wang9, Hong-Lian Ma8, Zu-Min Xu4, Ru-Biao Lu3, Xiao-Wu Deng3, Ming Chen10. 1. Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. Electronic address: baoyong@sysucc.org.cn. 2. Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. 3. Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. 4. Cancer Center, The Affiliated Hospital of Guangdong Medical College, Zhanjiang, China. 5. Department of Radiation Oncology, Fujian Provincial Tumor Hospital, Fuzhou, China. 6. Department of Radiation Oncology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China. 7. Department of Radiation Oncology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China. 8. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China. 9. Department of Radiation Oncology, Guangzhou General Hospital of Guangzhou Military Command, China. 10. Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. Electronic address: chenming@sysucc.org.cn.
Abstract
PURPOSE: The objective of this study was to evaluate the efficacy and safety of Endostar combined with concurrent chemoradiotherapy (CCRT) in patients with stage III non-small-cell lung cancer (NSCLC). METHODS: Patients with unresectable stage III NSCLC were treated with Endostar (7.5mg/m(2)/d) for 7days at weeks 1, 3, 5, and 7, while two cycles of docetaxel (65mg/m(2)) and cisplatin (65mg/m(2)) were administered on days 8 and 36, with concurrent thoracic radiation to a dose of 60-66Gy. Primary end points were short-term efficacy and treatment-related toxicity. RESULTS: Fifty patients were enrolled into the study, and 48 were assessable. Of the 48 patients, 83% had stage IIIB and 65% had N3 disease. Median follow-up was 25.0months. Overall response rate was 77%. The estimated median progression-free survival (PFS) was 9.9months, and the estimated median overall survival (OS) was 24.0months. The 1-, 2-, and 3-year local control rates were 75%, 67%, and 51%, PFS rates were 48%, 27%, and 16%, and OS rates were 81%, 50%, and 30%, respectively. All toxicities were tolerable with proper treatment. CONCLUSIONS: The combination of Endostar with CCRT for locally advanced NSCLC patients was feasible and showed promising survival and local control rates.
PURPOSE: The objective of this study was to evaluate the efficacy and safety of Endostar combined with concurrent chemoradiotherapy (CCRT) in patients with stage III non-small-cell lung cancer (NSCLC). METHODS:Patients with unresectable stage III NSCLC were treated with Endostar (7.5mg/m(2)/d) for 7days at weeks 1, 3, 5, and 7, while two cycles of docetaxel (65mg/m(2)) and cisplatin (65mg/m(2)) were administered on days 8 and 36, with concurrent thoracic radiation to a dose of 60-66Gy. Primary end points were short-term efficacy and treatment-related toxicity. RESULTS: Fifty patients were enrolled into the study, and 48 were assessable. Of the 48 patients, 83% had stage IIIB and 65% had N3 disease. Median follow-up was 25.0months. Overall response rate was 77%. The estimated median progression-free survival (PFS) was 9.9months, and the estimated median overall survival (OS) was 24.0months. The 1-, 2-, and 3-year local control rates were 75%, 67%, and 51%, PFS rates were 48%, 27%, and 16%, and OS rates were 81%, 50%, and 30%, respectively. All toxicities were tolerable with proper treatment. CONCLUSIONS: The combination of Endostar with CCRT for locally advanced NSCLCpatients was feasible and showed promising survival and local control rates.
Authors: F Couñago; A Rodríguez; P Calvo; J Luna; J L Monroy; B Taboada; V Díaz; N Rodríguez de Dios Journal: Clin Transl Oncol Date: 2016-04-22 Impact factor: 3.405
Authors: Weiheng Hu; Jian Fang; Jun Nie; Ling Dai; Jie Zhang; Xiaoling Chen; Xiangjuan Ma; Guangming Tian; Di Wu; Sen Han; Jindi Han; Yang Wang; Jieran Long Journal: Medicine (Baltimore) Date: 2016-07 Impact factor: 1.889
Authors: Ma Honglian; Hui Zhouguang; Peng Fang; Zhao Lujun; Li Dongming; Xu Yujin; Bao Yong; Xu Liming; Zhai Yirui; Hu Xiao; Wang Jin; Kong Yue; Wang Lvhua; Chen Ming Journal: Thorac Cancer Date: 2020-02-18 Impact factor: 3.500